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Selected Interim Summary Data:
CMV-speciﬁc
T-cells (3x104CD3+/kg)
Control
Patient disposition
enrolled (withdrawn)
35 (18) 17 (6)
Reasons for withdrawal
GvHD or steroids at baseline 6 4
Insufﬁcient starting material 8 -
Other 4 2
New onset GvHD
post visit 2
3 (17.6%) 3 (27.3%)
Fold change from baseline
(peak) in CMV speciﬁc
cells (mean +/- SEM)a
109.1 +/- 42.5 10.5 +/- 7.1
Absolute change from
baseline (peak) in CMV
speciﬁc cells/ml
(mean +/- SEM)b
20870 +/- 6766 4867 +/- 2533
a p ¼ 0.017; b p¼ 0.056
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Introduction: Qualitative and quantitative deﬁciencies in
T-cell mediated immunity following allogeneic HSCT are
associated with a high incidence of cytomegalovirus (CMV)
infection, which remains amajor cause of morbidity and cost,
and a signiﬁcant indirect cause of mortality in this setting.
Adoptive cellular therapy (ACT) can potentially expedite
reconstitution of virus-speciﬁc immunity, minimizing the
period of risk. A number of phase I-II studies have demon-
strated proof of concept for such strategies, although
estimation of efﬁcacy is limited by potential selection bias.
We therefore conducted a randomized controlled trial to
evaluate immune reconstitution and safety of CMV-speciﬁc
T-cells (CMV-ASPECT: ClinicalTrials.gov NCT01220895).
Methods: The study enrolled CMV-seropositive patients
>16 yrs old, undergoing T-cell depleted (alemtuzumab)
HSCT from unrelated CMV-seropositive donors in 9 UK
centers. Patient and donor were required to share one or
more of the following HLA alleles: A*0101, A*0201, A*2402,
B*0702 or B*0801; and the donor to demonstrate >0.1%
HLA-streptamer positive CMV-speciﬁc T-cells. Randomiza-
tion was then performed 2:1 in favor of the treatment arm.
CMV-speciﬁc cells were directly selected from an aliquot
of the stem cell donation after streptamer-labeling. CMV
surveillance was performed using quantitative PCR. Patients
with Gd 2 aGvHD or systemic steroid administration at
baseline (D28) were withdrawn. CMV-speciﬁc T-cells were
administered pre-emptively for CMV DNAemia. Both groups
received best available antiviral pre-emptive treatment ac-
cording to standardized intervention criteria. Patients were
followed for immune reconstitution (primary endpoint) and
safety.
Results: From Oct 2010 to Jun 2013, 52 patients/donors were
enrolled. As of Sep 2013, all subjects had completed immune
assessments at 8 weeks post CMV detection and ﬁnal follow-
up visits were underway. The complete study safety and
immune reconstitution data will be analyzed January 2014.
Conclusions: In this ﬁrst randomized trial of CMV speciﬁc
T-cells post-HSCT, adoptive cell therapy (Cytovir CMV)
proved safe and resulted in earlier and greater durableexpansion of CMV-speciﬁc T cells and reconstitution of
immunity. Further investigation is warranted to determine if
the observed increase in CMV-speciﬁc cells translates to
clinical beneﬁt.43
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Adoptive immunotherapy is an effective strategy for the
treatment of EBV+ lymphoproliferative diseases (EBV-LPD)
arising after allogeneic hematopoietic stem cell (HSCT) or
solid organ transplant (SOT). This approach is often limited
by an inability to generate donor derived in vitro expanded
EBV-speciﬁc cytotoxic T-lymphocyte (EBV-CTL) lines in a
timely manner and/or donor derived EBV CTLs being
restricted by non-shared HLA alleles in the patient.
We have treated 28 consecutive patients for EBV LPD with
in vitro expanded EBV-CTLs derived from a donor other than
the patient or their transplant (HSCT or SOT) donor. EBV CTLs
were selected from a bank of 345 lines generated under GMP
conditions from normal donors. Patients were recipients of
unmodiﬁed (n¼7), T cell depleted (n¼7) or unrelated cord
blood (n¼7) HSCT or one (n¼5) or two (n¼2) SOTs. Patients
received infusions of 3rd party EBV-CTLs after failing a
median of 2 prior therapies including rituximab in all but one
case. Three patients failed prior infusions with EBV-CTLs
which were autologous (n¼1) or derived from their original
HSCT donor (n¼2). In these two patients it was demon-
strated that the donor derived EBV CTLs were restricted by a
non-shared HLA allele.
Third party EBV-CTLs were selected on the basis of HLA
matching at a minimum of 2/8 recipient alleles. When
known, EBV-CTLs restricted through HLA alleles present on
